Table 1.
Novel significantly mutated genes not previously reported on in cervical carcinoma.
| Gene | Nonsilent mutations | Relative frequency | Patients | Unique sites | Missense mutation | Silent mutations | “LOF” mutationsa | FDR |
|---|---|---|---|---|---|---|---|---|
| KRT8 | 26 | 6% | 25 | 3 | 26 | 1 | 0 | 6.10E-06 |
| GPX1 | 12 | 3% | 11 | 3 | 11 | 1 | 1 | 2.57E-04 |
| ZC3H11A | 20 | 4% | 19 | 9 | 10 | 3 | 10 | 3.73E-04 |
| OTOP1 | 11 | 3% | 11 | 5 | 4 | 0 | 7 | 9.88E-03 |
| ARIH1 | 3 | 1% | 3 | 1 | 0 | 0 | 3 | 1.05E-02 |
| COIL | 10 | 2% | 9 | 7 | 5 | 0 | 5 | 1.05E-02 |
| TBC1D26 | 9 | 2% | 8 | 3 | 9 | 1 | 0 | 1.68E-02 |
| RANBP2 | 29 | 6% | 26 | 23 | 24 | 5 | 5 | 2.15E-02 |
| POTEC | 26 | 6% | 24 | 13 | 23 | 3 | 3 | 2.52E-02 |
| SPRED3 | 7 | 2% | 7 | 1 | 0 | 0 | 7 | 3.45E-02 |
| BMS1 | 15 | 3% | 15 | 10 | 14 | 4 | 1 | 5.29E-02 |
| DNAH12 | 10 | 2% | 10 | 9 | 5 | 2 | 5 | 5.49E-02 |
| MSN | 26 | 6% | 26 | 8 | 25 | 16 | 1 | 5.49E-02 |
| NBPF10 | 35 | 8% | 33 | 26 | 29 | 23 | 6 | 5.49E-02 |
| FAM155A | 7 | 2% | 7 | 4 | 2 | 0 | 5 | 7.68E-02 |
a”LOF” represents “loss of function” mutations, a category that includes nonsense, indel, and frameshift mutations.